American Heart scientific sessions and ALN-PCSsc, an RNAi Investigational Agent

I'm here at the 2015 American Heart Association Scientific Sessions and will bring you many many key points in the next 2 weeks. This meeting is filled with science and results and fascinating new medicines, SPRINT to new blood pressure goals, measurements such as TIMI and DAPT risk scores and so much more.

The last late breaking clinical trial session happens at 10:45 Nobember 11, 2015. It would be important enough in that some of the best science is saved to the end, but this session is more important because of an investigational medicine called ALN-PCSsc, an RNAi type drug.

I'll return to writing once the session closes and information is released, but I think this new PCSK9 inhibitor may show data on dosing once every 3 months and perhaps even once every 6 months. The effect of this experimental drug on a variety of laboratory tests should also be released! 

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.